002821 Asymchem Laboratories(Tianjin)Co.,Ltd.
Closed 10-23 15:00:00
146.22
+6.56
+4.70%
High147.30Low136.21Vol10.74M
Open137.00D1 Closing139.66Amplitude7.94%
Mkt Cap52.93BTradable Cap46.35BTotal Shares362.00M
T/O1.52BT/O Rate3.39%Tradable Shares317.00M
P/B2.85ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Asymchem Laboratories Posts Higher Q3 Attributable Profit; Revenue Up
MT Newswires Live  ·  10-22 17:54
Asymchem Laboratories Posts Higher Q3 Attributable Profit; Revenue Up
China's Asymchem Q3 Revenue, Net Profit Rise on Macromolecules Strength
Reuters  ·  10-22 17:40
China's Asymchem Q3 Revenue, Net Profit Rise on Macromolecules Strength
Asymchem Reports 6.49% Rise in First Three Quarters Net Profit Attributable to Shareholders, Reaching Approximately RMB 852 Million
Stock News  ·  10-22 17:36
Asymchem Reports 6.49% Rise in First Three Quarters Net Profit Attributable to Shareholders, Reaching Approximately RMB 852 Million
Asymchem Laboratories (Tianjin) Q3 Revenue RMB 1,788.09416 Million
THOMSON REUTERS  ·  10-22 17:29
Asymchem Laboratories (Tianjin) Q3 Revenue RMB 1,788.09416 Million
Asymchem Laboratories (Tianjin) Q3 Net Profit up 81.5% Y/Y
THOMSON REUTERS  ·  10-22 16:56
Asymchem Laboratories (Tianjin) Q3 Net Profit up 81.5% Y/Y
Hong Kong Stocks Midday Review: Hang Seng Index Slips 0.04% in Morning Session, CRO-Related Shares Lead Gains
Stock News  ·  09-30
Hong Kong Stocks Midday Review: Hang Seng Index Slips 0.04% in Morning Session, CRO-Related Shares Lead Gains
Schroders PLC Trims Stake in Asymchem Laboratories, Selling 175,800 Shares at Roughly HK$150.23 Each
Stock News  ·  09-27
Schroders PLC Trims Stake in Asymchem Laboratories, Selling 175,800 Shares at Roughly HK$150.23 Each
JPMorgan Chase & Co's Long Position in H-Shares of Asymchem Laboratories (Tianjin) Decreases to 7.82% on Sept 14 from 8.86% - HKEX
THOMSON REUTERS  ·  09-17
JPMorgan Chase & Co's Long Position in H-Shares of Asymchem Laboratories (Tianjin) Decreases to 7.82% on Sept 14 from 8.86% - HKEX
CRO Sector Shares Surge in Morning Trading With Asymchem and Tigermed Leading the Charge
Deep News  ·  09-14
CRO Sector Shares Surge in Morning Trading With Asymchem and Tigermed Leading the Charge
Southern Fund Boosts Asymchem Stake With HK$3.5 Million Purchase
Deep News  ·  09-13
Southern Fund Boosts Asymchem Stake With HK$3.5 Million Purchase
Southern Fund Trims Stake in Asymchem with Share Sale at HK$134 Each
Deep News  ·  09-11
Southern Fund Trims Stake in Asymchem with Share Sale at HK$134 Each
JPMorgan Reduces Stake in Asymchem, Selling 82,300 Shares at HK$127.7 Each
Stock News  ·  09-08
JPMorgan Reduces Stake in Asymchem, Selling 82,300 Shares at HK$127.7 Each
凯莱英午后强势攀升逾5%，新兴业务毛利大幅改善，全年增长引擎蓄势待发
Stock News  ·  09-02
凯莱英午后强势攀升逾5%，新兴业务毛利大幅改善，全年增长引擎蓄势待发
Southern Fund Trims Stake in Asymchem Laboratories with Share Sale Priced at Approximately HK$110.77
Deep News  ·  08-31
Southern Fund Trims Stake in Asymchem Laboratories with Share Sale Priced at Approximately HK$110.77
Southern Fund Management Reduces Stake in Asymchem, Selling 52,100 Shares at Approximately HK$110.77 Each
Stock News  ·  08-28
Southern Fund Management Reduces Stake in Asymchem, Selling 52,100 Shares at Approximately HK$110.77 Each
JPMorgan Trims Asymchem Stake with HK$33.99M Share Disposal
Stock News  ·  08-28
JPMorgan Trims Asymchem Stake with HK$33.99M Share Disposal
JPMorgan Boosts Stake in Asymchem With 124,800-Share Purchase at HK$112.5 Apiece
Stock News  ·  08-27
JPMorgan Boosts Stake in Asymchem With 124,800-Share Purchase at HK$112.5 Apiece
Southern Fund Management Boosts Stake in Asymchem with HK$4.18M Share Purchase
Stock News  ·  08-27
Southern Fund Management Boosts Stake in Asymchem with HK$4.18M Share Purchase
Asymchem Grants 2.711 Million Class A Restricted Shares to 622 Employees
Stock News  ·  08-25
Asymchem Grants 2.711 Million Class A Restricted Shares to 622 Employees
Market Sentiment Stabilizes as Sanctions Prove Largely Symbolic; Tech Benchmarks Surge on Potential Dovish Fed Signals
Stock News  ·  08-25
Market Sentiment Stabilizes as Sanctions Prove Largely Symbolic; Tech Benchmarks Surge on Potential Dovish Fed Signals

Introduction

Company Name.
凯莱英医药集团(天津)股份有限公司
Industry:
医药制造业
Listing Date:
2016-11-18
Main Business:
　　凯莱英医药集团(天津)股份有限公司的主营业务是为国内外制药公司、生物技术公司提供药品全生命周期的一站式服务。公司的主要产品是小分子CDMO解决方案、新兴业务。截至报告期末，公司累计获得国内外已授权专利597项，其中国内专利450项，国外专利147项；其中216项在合成生物领域，216项在连续技术反应领域。新技术研发论文多次在自然科学领域最权威的三大学术期刊之《自然》及其他行业重要期刊《美国化学会志》、《德国应用化学》、《有机化学》、《有机化学通讯》等国际行业领先期刊获得发表，已累计发表52篇，其中16篇的影响因子超过10。
Issue price:
30.53